Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]